What we will cover. HIV in Case 1. HIV drugs frequently cause drug reactions. What is the most likely diagnosis

Similar documents
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

ART and Prevention: What do we know?

PHCP 403 by L. K. Sarki

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

Natural history of HIV Infection

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

Nothing to disclose.

Update on Antiretroviral Treatment for HIV Infection 2008

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

Simplifying HIV Treatment Now and in the Future

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

The Hospitalized HIV+ Patient

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

Cases AMC HIV/HCV Conference 2015

Comprehensive Guideline Summary

Industry Data Request

HIV and AIDS An update

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

Antiretroviral Dosing in Renal Impairment

Year 2002 Paper two: Questions supplied by Jo 1

HIV Drugs and the HIV Lifecycle

HIV Clinical Nurse Specialist CCDHB Wellington

Actualización y Futuro en VIH

Industry Request Integrase Inhibitors

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV

COMPETING INTEREST OF FINANCIAL VALUE

Continuing Education for Pharmacy Technicians

Principles of Antiretroviral Therapy

The Global HIV Epidemic. Jerome Larkin, MD

I. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

TB/HIV Co-Infection. Tuberculosis and HIV

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions

HIV medications HIV medication and schedule plan

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM

U=U NHIVNA HIV, Fertility and Contraception in the era of

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

BHIVA Audit Survey of patient assessment and monitoring. starting ART from naïve. Survey of patient assessment and monitoring

What does the HIV Pharmacy Team need to know about PEP

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

MANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE

Criteria for Oral PrEP

Post Exposure Prophylaxis for HIV following Sexual Exposure (PEPSE) Assessment Proforma PART A: FOR COMPLETION AT INITIAL PRESENTATION

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

1. E-learning: NHIVNA HIV modules on the NHIVNA website

Testing for HIV in Practice - Seminar. Case History. 19 year old black African patient registered with the practice 5 years (since age 14).

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

The impact of antiretroviral drugs on Cardiovascular Health

HIV epidemiology since HIV in the United States. HIV Transmission

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

medical monitoring: clinical monitoring and laboratory tests

Pharmacological considerations on the use of ARVs in pregnancy

Blood-Borne Pathogens and Post-Exposure Prophylaxis

Selected Issues in HIV Clinical Trials

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

Downloaded from:

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Cost impact of an HIV MDT for managing anti-retroviral switch

Objectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

HIV Management Update 2015

Central Nervous System Penetration of ARVs: Does it Matter?

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Susan L. Koletar, MD

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

Pediatric Antiretroviral Resistance Challenges

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

HIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

HIV associated CNS disease in the era of HAART

HIV Treatment: State of the Art 2013

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

Selected Issues in HIV Clinical Trials

HIV in in Women Women

Occupational and Non- Occupational HIV Post-exposure Prophylaxis

HIV & Aging: Evolving Clinical Considerations in the New Millennium

TO DECREASE THE CHANCE OF GETTING

HIV and AIDS. Shan Nanji

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012


BHIVA antiretroviral treatment guidelines 2015

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

HIV IN OKLAHOMA MAKING A DIFFERENCE

Nobel /03/28. HIV virus and infected CD4+ T cells

COMPETING INTEREST OF FINANCIAL VALUE

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV

Sasisopin Kiertiburanakul, MD, MHS

Transcription:

HIV in 2009 Susan Hopkins Consultant in Infectious Diseases & Microbiology Royal Free Hampstead NHS Trust What we will cover Not Opportunistic Infections Important adverse events Important points to consider in A&E CCR5 antagonists Maraviroc Integrase inhibitors Elvitegravir Raltegrevir Protease inhibitors Atazanivir Darunivir Fosamprenavir Indinavir Ritonavir Lopinivir Nelfinavir Saquinivir Tipranavir Fusion inhibitors Enfurvitide (T20) Reverse transcriptase inhibitors Abacavir Didanosine Emtricitabine Lamividine Stavudine Tenofovir Zidovidine Delaviridine Efaverinz Etravirine Nevirapine Case 1. 35 year old gay white man HIV positive CD4=180 Recently started antiretrovirals Kivexa (abacavir/lamivudine) Efavirenz 4/7 progressive fever, rash, abdominal pain Bloods: Bili 44 AST 350 ALT 424 Hb 10.9 WCC 2.5 Plts 140 De Clercq Nature Reviews 2007 What is the most likely diagnosis 1. Acute Hepatitis B 2. Cytomegalovirus infection 3. Parvovirus infection 4. Drug reaction 5. Syphilis drug reaction which drug? HIV drugs frequently cause drug reactions 1

HIV drugs frequently cause drug reactions drug reaction which drug? abacavir hypersensitivity syndrome predicted by HLA B570*1 (Caucsians) can be fatal can be quickly fatal on rechallenge efavirenz rash and liver toxicity well recognised Efavirenz Monotherapy = NNRTI CLASS RESISTANCE Mutations can be found in minor variants in ~70% Efavirenz Monotherapy = NNRTI CLASS RESISTANCE Mutations can be found in minor variants in ~70% Call HIV doctor In large centre 24/7; In DGH first thing in the morning Consider other drugs Prevents resistance developing during washout Case 2 46 yo male ex-ivdu, still smokes marijuana HIV+ HCV+ 14 years Kivexa (Abacavir/ Lamividine), Kaletra (Lopinivir/r), Methadone VL<50 CD4>300 Presents to A&E with painful left leg and intermittent chest pain at rest 2

What is your most likely diagnosis? 1. 2. 3. 4. 5. Cardiac Risk Factors DVT & PE Mycotic aneursym in L groin with emboli Peripheral vascular disease & IHD Infective Endocarditis with embolisation to L leg Nothing just wants opiates Cardiovascular disease increasing Protease inhibitors more associated with CVS events Increased CVS risk with time on HAART RR 1 9 (1 5 2 5) ddi RR 1 5 (1 1-2.0) HIV Antiretrovirals Hyperlipidaemia -> Treatment So he needs secondary prevention. Which drug is contraindicated? 1. 2. 3. 4. 5. - related to lipids, glucose, and other factors Abc Male >40 years Family History Smoker Perindopril Simvastatin Atenolol Aspirin Clopidrogel Sabin et al, for D:A:D, Lancet 2008 Cooper Aids 2008 Cytochrome p450 Chemically oxidise or reduce drugs 4 major families, 6 sub-families e.g 3A4, 2D6 Inhibition: Competitive (rev) or Mechanism (irrev) Induction: Increased synthesis of enzyme Enzyme inhibition 1st dose Enzyme induction 2-7d All protease inhibitors = 3A4 Ritonavir most potent PIs: Ritonavir, Nelfinavir NNRTIs 3

Inform HIV team & pharmacist too BHIVA Mortality audit 2004-5 Bacterial sepsis PCP TB Other OI Lymphoma KS Dementia Other malignancy Multiorgan end-stage HIV CVD Renal Other disease probably related to HIV Chronic liver disease due to co-infection/alcohol Suicide Accident/injury Overdose Other, not related to HIV Not known Renal disease & HIV ARF in 20% HIV hospitalised patients (cf 3-5%) Ambulatory care: Incidence 5.9 per 1000 person-yrs Causes Azotemia/ ATN HIVAN- classically FSGS Interstitial nephritis secondary to drugs used to treat OI ARV Drugs Tenofovir: ARF, Fanconi Syndrome, Nephrogenic DI Indinavir: crystalluria, renal calculi Risk factors Male, Hepatitis C, IVDU, Antivirals HIV, AIDS defining illnesses Top bars: reclassified during audit Bottom bars: as initially reported 0% 2% 4% 6% 8% 10% 12% 14% Percentage of patients 4

Case 3. 24 yo man attends A&E on Friday night Says that a condom burst during sex in a darkroom in London the previous night Otherwise well No medical problems Last STI screen & HIV test 6 months ago What do you advise? 1. Hepatitis B vaccination 2. HIV test 3. Post exposure prophylaxis 4. Attend GU OPD Monday morning 5. Go to his GP 6. Tell him he s wasting your time HIGH MEDIUM LOW Did sexual exposure occur <72 hours ago? Assess risk that source is HIV+ Y Known HIV+ MSM (London/ Manchester) Hetero (SSA) IVDU MSM Hetero (Asia, E Europe etc) Other hetero/ivdu Low Medium High Low No PEPSE Assess risk of exposure Repeated exposure additive risk HIGH MEDIUM LOW Medium N Rape Receptive anal intercourse Sharing injecting equipment Blood transfusion Receptive vaginal NSI Other sex Mucus membrane exposure High Review by trained individual Starter pack Refer to HIV service Do baseline bloods Check/give Hep B immunisation NO PEP Fisher et al Int J STD & AIDS 2006 Summary Points 1. HIV drugs have frequent serious adverse events 2. with HIV specialist before you stop HIV drugs 3. Many HIV drugs are enzyme inducers and enzyme inhibitors 4. Before prescribing new drugs click on www.hivdruginteractions.co.uk 5. HIV patients increasingly present with non-hiv related diseases 6. HIV and ARV independent risk factors for cardiovascular disease 7. Renal disease x 3 in HIV+ compared to age matched controls 8. Patients presenting post sexual exposure need PEP assessment 5